2171.HK | CARsgen Therapeutics Holdings Limited Annual &

Annual Income Statements

(In CNY)

Breakdown	2023	2022	2021	2020	2019
Revenue	-	-	25.81 Million	-	-
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	25.81 Million	-	-
Operating Expenses	767.64 Million	802.28 Million	611.8 Million	348.66 Million	230.35 Million
Selling, General and Administrative Expenses	133.31 Million	46.82 Million	65.81 Million	54.8 Million	8.75 Million
Research and Development Expenses	661.65 Million	680.3 Million	501.72 Million	281.75 Million	210.2 Million
Other Expenses	-27.32 Million	75.15 Million	44.26 Million	12.11 Million	11.4 Million
Cost and Expenses	767.64 Million	802.28 Million	611.8 Million	348.66 Million	230.35 Million
Operating Income	-767.64 Million	-881.29 Million	-585.98 Million	-327.04 Million	-227.4 Million
Interest Expense	-	15.52 Million	10.86 Million	13.48 Million	887 Thousand
Income Tax Expense	407 Thousand	1.29 Million	7.64 Million	737.76 Million	39.16 Million
Earnings before Tax	-747.38 Million	-890.95 Million	-4.73 Billion	-1.06 Billion	-265.13 Million
Net Income	-747.79 Million	-892.24 Million	-4.74 Billion	-1.8 Billion	-304.29 Million
Earnings Per Share Basic	-1.34	-1.62	-8.63	-8.55	-5.36 Million
Earnings Per Share Diluted	-1.34	-1.62	-8.63	-8.55	-5.36 Million
Weighted Average Shares Outstanding	556.12 Million	551.62 Million	549.88 Million	210.69 Million	56.73
Weighted Average Shares Outstanding (Diluted)	556.12 Million	551.62 Million	549.88 Million	210.69 Million	56.73
Gross Margin	-	-	1.00	-	-
EBIT Margin	-	-	-20.06	-	-
Profit Margin	-	-	-183.80	-	-
EBITDA	-717.63 Million	-793.89 Million	-517.89 Million	-286.17 Million	-206.4 Million
Earnings Before Tax Margin	-	-	-22.70	-	-

Breakdown	2024 Q2	2024 Q1	2023 Q4	2023 FY	2023 Q3	2023 Q2
Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	49.82 Million
Gross Profit	-	-	-	-	-	-49.82 Million
Operating Expenses	-	-	187.77 Thousand	815.51 Million	187.77 Thousand	219.98 Thousand
Selling, General and Administrative Expenses	-	-	35.24 Thousand	-	35.24 Thousand	31.41 Thousand
Research and Development Expenses	-	-	169.17 Thousand	-	169.17 Thousand	161.65 Thousand
Other Expenses	-	-	-	-	-	-
Cost and Expenses	-	-	187.77 Thousand	815.51 Million	187.77 Thousand	219.98 Thousand
Operating Income	-	-	-205.17 Thousand	-785.04 Million	-205.17 Thousand	-187.35 Thousand
Interest Expense	-	-	-	-	-	2.87 Million
Income Tax Expense	-	-	203.50	407 Thousand	203.50	-
Earnings before Tax	-	-	-171.45 Thousand	-747.38 Million	-171.45 Thousand	-202.23 Thousand
Net Income	-	-	-171.66 Thousand	-747.79 Million	-171.66 Thousand	-202.23 Thousand
Earnings Per Share Basic	-	-	-0.00	-	-0.00	-0.00
Earnings Per Share Diluted	-	-	-0.00	-	-0.00	-0.00
Weighted Average Shares Outstanding	556.77 Million	556.77 Million	556.77 Million	556.12 Million	556.77 Million	555.47 Million
Weighted Average Shares Outstanding (Diluted)	556.77 Million	556.77 Million	556.77 Million	556.12 Million	556.77 Million	555.47 Million
Gross Margin	-	-	-	-	-	-
EBIT Margin	-	-	-	-	-	-
Profit Margin	-	-	-	-	-	-
EBITDA	-	-	-188.15 Thousand	-	-188.15 Thousand	-170.66 Thousand
Earnings Before Tax Margin	-	-	-	-	-	-